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Abstract
According to the latest knowledge, hereditary kidney cancers may account for 5–8% of all
kidney cancers, and it may be more common than previously thought. Hereditary RCC is
often characterized by an early age of onset (approximately 45 years), typical histological
pattern, and frequently the bilaterality and multicentricity of the primary tumor. Wilms’
tumor (nephroblastoma) is the most common kidney tumor of childhood. More than 15
syndromes with inherited susceptibility to kidney cancer are known, and there are over 25
known genes associated with them. Most of these are dominantly inherited in which the
offspring of the proband has a 50% chance of inheriting a gene mutation with susceptibil-
ity to kidney cancer. The aggressiveness of hereditary RCCs and recommended surgery
varies depending on the syndrome and mutation type. Also, systemic therapy may be
optional. Multigene next generation sequencing (NGS) panel technology allows genes of
interest to be studied quickly and cost-effectively. Sequencing investigations have
improved the accuracy of hereditary cancer diagnoses. Diagnostic utility has been hugely
increased by multigene NGS panels. It is important to identify hereditary cancer suscepti-
bility, because the risk of cancer in the mutation carriers can be reduced. In this review
article, the latest literature on syndromes subjecting to hereditary kidney cancer and
recommended follow-up is summarized.
Keywords: von Hippel-Lindau, hereditary papillary RCC, hereditary leiomyomatosis
and RCC, Birt-Hogg-Dubé, Wilms’ tumor, hereditary kidney cancer syndromes,
genetic susceptibility
1. Introduction
Kidney cancer is the 16th most common cancer worldwide with over 400,000 cases in 2018
representing approximately 2.2% of all diagnosed malignancies worldwide [1]. The majority of
primary renal malignancies are renal cell carcinomas (RCCs) with most of the remaining
comprising upper tract urothelial carcinoma (UTUC). The mean age of onset of RCC is
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
approximately 60–70 years. The most common kidney tumor of childhood is Wilms’ tumor
(nephroblastoma). In the European Union, the estimated annual number of new kidney can-
cers is approximately 46,000 [2]. Etiologic risk factors for kidney cancer development are male
sex, obesity, and tobacco, in addition to hypertension [3–5], acquired cystic kidney disease [6],
and inherited susceptibility. Prognostic factors of different protein and gene expressions in
RCC have been studied [7, 8].
According to the latest knowledge, hereditary kidney cancers may account for 5–8% of all
kidney cancers [9], and it may be more common than previously thought [10]. In those RCC
patients without clear cell RCC (ccRCC) subtype, the amount of germline high-risk mutations
is greater, 12% [11]. Susceptibility to kidney cancer may be caused by high-risk, moderate-risk,
or low-risk gene mutation [12]. Even the carriership of high-risk gene mutation does not
always lead to kidney cancer. The risk for kidney cancer (penetrance) varies in different
syndromes. In some cases, the predisposed genetic factor to kidney cancer is chromosomal
aberration, for example, as in constitutional chromosomal 3 translocation with 6 or 8 of family
(Table 2). In hereditary cancer, the impact of environmental factors is small.
More than 15 syndromes with inherited susceptibility to kidney cancer are known, and there
are over 25 known genes associated with them. Most of these are dominantly inherited in
which the offspring of the proband has a 50% chance of inheriting a gene mutation with
susceptibility to kidney cancer.
2. Identifying hereditary kidney cancer
Hereditary kidney cancer syndrome is often characterized by an early age of onset (approxi-
mately 45 years) [30], typical histological pattern, and frequently the bilaterality and
multicentricity of the primary tumor (Table 1). By evaluating the family history of diagnosed
cancer cases, benign tumors, and diagnostic gene test results, it is possible to identify families
with hereditary kidney cancer (Tables 2 and 3).
It is possible that there exists only a single hereditary cancer syndrome case in the family due
to de novo mutations (autosomal dominant) which means that the person’s parents do not
have the same mutation. There are hot spot regions in genes where mutation can easier
develop during meiosis of germ cells. In addition to this, the risk of hereditary kidney cancer
Multiple close relatives with benign or malign tumors of the syndrome
Atypically young age of onset for tumors of the syndrome
Relative with two tumors of the syndrome (two examples below)
• RCC and uterine leiomyosarcoma
• Colon cancer or endometrial carcinoma in the uterus and upper tract urothelial carcinoma
Typical histological finding (e.g., rare subtype or multiplicity) or clinical picture
Table 1. Factors suggesting inherited cancer syndrome.
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is linked to some congenital multisystem syndromes, such as Beckwith-Wiedemann syndrome
and tuberous sclerosis (Table 4). When such a multisystemic syndrome is detected, appropri-
ate follow-up care is provided as with hereditary kidney cancer families.
It is suspected that hereditary kidney cancer is underdiagnosed. Identifying the families with
increased risk for kidney cancer allows clinicians to improve the prognosis of persons with
genetic cancer susceptibility. This review discussed the characteristics of inherited kidney
cancer and how to improve their prognosis (Table 5).
3. Basic cancer genetics
In hereditary and sporadic cancer, the normal genome regulation is impaired [34], and cancer
susceptibility is caused by both inherited germline gene mutations and somatic gene mutations
in tissue that occurred over time. However, in sporadic cases the inherited gene mutations
cause low risk for kidney cancer [35]. Of all clear cell-type RCCs (sporadic or hereditary), 75%
have a somatic mutation in the von Hippel-Lindau tumor suppressor gene (VHL) in the short
von Hippel-Lindau
(VHL)
Hereditary
papillary RCC
(HPRC)
Hereditary
leiomyomatosis and
RCC (HLRCC)
Birt-Hogg-Dubé
(BHD)
Constitutional
chromosomal
3 translocation
RCC
subtype
Clear cell carcinoma Papillary type 1 Papillary type 2,
collecting duct
Most often
chromophobe 
oncocytoma
Clear cell
carcinoma
Risk for
RCC
40% Nearly 100% 20–30% 30% 30%
Gene VHL MET FH FLCN(BHD)
Typical
age of
onset for
RCC
40 years 50–70 years Less than 40 years 50 years
Biology of
RCC
Bilaterality, multiple
tumors
Bilaterality,
multiple tumors,
microscopic
lesions as much
as 1000
Unilaterality, solitarity,
aggressive, highly
potential to metastasize
Bilaterality, multiple
tumors
Bilaterality,
multiple
tumors
Typical
surgery
Minimal invasive Minimal invasive
or radical
nephrectomy
Radical nephrectomy Minimal invasive
Other
signs of
the
syndrome
than RCC
Retinal
hemangioma/CNS
hemangioblastoma,
pheochromocytoma
None Uterine leiomyomas in
almost every patient,
uterine leiomyosarcoma,
cutaneous leiomyomas
Cutaneous hair
follicle benign tumors
and pulmonary cysts
in almost every
patient
Thyroid,
bladder,
pancreatic and
gastric cancer
Reference [13, 14] [15, 16] [17–20] [21, 22] [23]
Table 2. Hereditary cancer syndromes in which the kidney cancer risk is high.
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Tuberous sclerosis Beckwith-Wiedemann syndrome Perlman syndrome
Kidney cancer
subtype
Clear cell, papillary, chromophobe Wilms’ tumor Wilms’ tumor
Risk for kidney
cancer
Less than 5% Around 5% 30–60%
Gene TSC1, TSC2 CDKN1C DIS3L2
Typical age of
onset for kidney
cancer
35 years Primarily in the first 8 years of life Neonatally
Inheritance Autosomal dominant Autosomal dominant, sporadic Autosomal recessive
Other signs of
the syndrome
than kidney
cancer
Renal angiomyolipomas,
hypopigmentation, seizures, learning
difficulties, angiofibromas, shagreen
patches, oral mucosal lesions,
subependymal giant cell astrocytoma
Neonatal hypoglycemia,
macrosomia, macroglossia,
hemihyperplasia, omphalocele,
renal abnormalities
Fetal ascites,
macrosomia,
visceromegaly,
generalized hypotonia
References [31, 32] [33] [33]
Table 4. Congenital multisystem syndromes with susceptibility for the kidney cancer.
Lynch
syndrome
Cowden
syndrome
Hyperparathyroid
jaw tumor
syndrome
Hereditary
pheochromocytoma
and paraganglioma
Li-Fraumeni
syndrome
BAP1 tumor
predisposition
syndrome
Kidney
cancer
subtype
Upper
tract
urothelial
carcinoma
Clear cell,
papillary,
chromophobe
Papillary type 1
RCC, adult Wilms’
tumor
Clear cell RCC,
chromophobe RCC,
oncocytoma
RCC and
Wilms’
tumor
Clear cell RCC
Risk for
kidney
cancer
Multiple 15% Uncommon 10% Low 10%
Gene MLH1,
MSH2,
MSH6,
PMS2,
EPCAM
PTEN CDC73 SDHB, SDHC, SDHD p53 BAP1
Other
signs of
the
syndrome
than RCC
Bowel
cancer,
uterine,
ovarian
cancer
Mucocutaneous
papules,
hamartomas,
macrocephaly,
thyroid
cancer, uterine
cancer,
intestinal
polyps
Ossifying jaw
fibromas, renal cysts,
parathyroid
adenoma/carcinoma,
uterine tumors
Paragangliomas,
pheochromocytoma,
GIST
Brain tumor,
sarcoma,
leukemia and
other cancer
types
Uveal and
cutaneous
melanoma,
mesothelioma
Reference [24] [25] [26] [27] [28] [29]
Table 3. Hereditary cancer syndromes in which the kidney cancer risk is moderate or low.
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arm of chromosome [36]. According to Vogelstein’s research group, chance has a major impact
in the development of cancer-causing mutations during DNA replication in normal,
noncancerous stem cells [37]. Current understanding is that about four to seven mutations in
key driver genes is sufficient to cause cancer to develop [38].
Genes associated with cancer predisposition are oncogenes or tumor suppressor genes. Onco-
genes act as gain of function. Mutation in the other allele is sufficient to produce the altered
protein. An example of this is theMET oncogene, in which mutation predisposes to hereditary
papillary renal cell carcinoma (HPRC) (Table 2). However, typically inherited cancer predis-
position is caused by the loss of function of tumor suppressor gene. In nearly all cases, the
mutations in tumor suppressor genes function recessively at the cellular level, following
Knudson’s theory of two hits [39]. Therefore, both alleles must lose function before the carci-
nogenesis may occur. The first mutation associated with the syndrome, the germline mutation,
passes the susceptibility to cancer to the next generation (nearly always) according to the
autosomal dominant inheritance and is situated in all the persons’ cells. The mutation in the
other allele in the same gene occurs during life. The penetrance of the inherited mutation is
decreased. Therefore, only part of the mutation carriers will be affected, but the risk of cancer is
many times higher than in an average population (Tables 2 and 3).
Caretaker genes are responsible for genomic stability by detecting damage to the genome, such
as single- or double-stranded DNA breaks [40]. Disruption in these genes leads to genomic
instability: an increase in the number of spontaneous mutations that cause new mutations in
oncogenes and growth restriction genes. Mutations in the caretaker genes are responsible for a
number of cancer susceptibility syndromes. For example, germline mutation in the growth
restriction gene MLH1 exposes for Lynch syndrome, which is associated with a high risk of
colon and endometrial carcinoma in the uterus and multiple risk for urothelial carcinoma
compared to an average population [24, 41]. Gatekeeper genes control cell growth. Normally,
a mutation in a gatekeeper gene activates the caretaker genes to participate in repair [34].
However, if this repair does not work, mutation in the gatekeeper gene will result in tumor
formation. For example, p53 acts as a gatekeeper, and its mutation exposes it to several types of
cancers, such as RCC (Table 3).
The aim is to improve the early detection of cancer
Occurrence can be prevented by removing the precursors identified in the monitoring
• In the carriers of Lynch syndrome mutation, removal of colon adenomas decreases the risk of colon cancer
Occurrence can be prevented by surgical procedures
• In the carriers of Lynch syndrome mutation, removal of uterus by menopause decreases the risk of endometrial
carcinoma in uterus
Sometimes genetic information can guide the choice of medication
• In the carriers of p53 mutation, radiation therapy and X-ray imaging will be avoided
Table 5. How to improve prognosis in the carriers of hereditary gene mutation.
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Genetics of cancer is only partially known. Advanced technological methods can detect previ-
ously unknown mutations in germline and tumors. Knowledge of the biology of hereditary
cancer also increases the understanding of sporadic cancers, as the same disease genes are
found in hereditary and non-hereditary cancers: e.g., mutated MET is a driver gene in hered-
itary and sporadic papillary renal carcinomas [42], and mutated WT1 is observed both in
sporadic and hereditary Wilms’ tumor. Novel genes and variants may be explored by whole
exome (WES) or genome research (WGS), where also noncoding regions are examined, in
scientific research projects. Identifying low-risk variants requires data from thousands of
patients and controls, which are investigated in genome-wide association studies (GWAS).
4. Genetic counseling and supporting families with hereditary cancer
It is important to identify hereditary cancer susceptibility, because the risk of cancer, morbidity,
and mortality in the mutation carriers can be reduced both in cancer patients and healthy
relatives in the family. If the family mutation is known, healthy family members with mutation
can participate in preventive studies. If the person does not have the known family mutation,
there is no need to have follow-up care because the risk of the cancer is the same as for an
average population.
Diagnostic gene testing on cancer patients is carried out in the clinical genetic units, but
diagnostic genetic testing can also be ordered by a treating oncologist or surgeon for patients
with kidney cancer. There are established principles for considering genetic testing in the case
of suspected hereditary cancer susceptibility (Table 6) [43]. If there is a genetic test that is
appropriate for the situation, the American Society of Clinical Oncology (ASCO) recommends
access to genetic testing. Before testing the individuals, informed consent should be requested
after adequate information and counseling [44]. For genetic testing the patient’s peripheral
blood, lymphocyte DNA is examined for identifying a possible hereditary mutation.
The investigation for finding the family mutation is always started with the affected person. A
medical geneticist will determine who could have mutation with increased kidney cancer risk
Hereditary cancer is suspected
The result of the gene test should be adequately interpreted
Gene testing has one of the following benefits:
• Improves diagnosis
• Guides to the appropriate medical surveillance for the carriers of gene mutation
• Provides information about strategies for prevention in the carriers of gene mutation
The ASCO has provided guidance on when genetic testing for cancer families should be considered [43]. The following
three conditions should be met. If the family mutation is found, the access for healthy relatives to genetic counseling
should be arranged.
Table 6. ASCO 2010 criteria for genetic testing.
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in the family. If there are no surviving cancer patients in the family, with the permission of the
relative, from the pathology department, a sample of the deceased person may be requested to
have healthy tissue DNA for genetic examination.
The result of the genetic testing gives information about the cancer risk of relatives. Healthy at-
risk relatives should have access to genetic counseling and predictive genetic testing after
counseling if they decide (Council of Europe’s The Convention on Human Rights and Biomed-
icine in Article 12, 1997). The clinical genetics units offer this service. The geneticist will have
the opportunity to provide the laboratory with reliable information about the family mutation
and arrange for the laboratory the DNA sample of the family’s index patient, which is a control
sample, positive control, to obtain a reliable test result. Counseling before predictive genetic
testing is nondirective and includes insight of the patient and the family. In counseling, the
patient and family receive not only information but also support. Increased anxiety or distress
has been documented in both counselors and their families around testing when investigating
hereditary VHL susceptibility [45]. The Genetic Information Nondiscrimination Act of the
Council of Europe’s Convention in Article 11, in 1997, was passed to prevent forms of genetic
discrimination by employment and health insurance. The Council of Europe’s Convention
prohibits the transfer of genetic information to employers in order to prevent employment
discrimination. Insurance discrimination is discussed in counseling. In Finland, genetic testing
is organized by public health care, which is why very few gene tests are conducted privately.
Participation in predictive genetic testing has been studied in the Finnish Lynch syndrome
families, which are at high risk for colorectal cancer and endometrial carcinoma in the uterus.
Approximately 80% of the members of the family participated in genetic counseling, and 95%
of them performed genetic prediction [46]. The main reasons for participating in predictive
genetic testing are the potential for cancer detection in surveillance monitoring, improved
treatment options in many Lynch syndrome cancer types, and improved cancer prognosis.
After the genetic testing, the counselor should always receive an interpretation of the significance
of the genetic test result [43, 44]. Different mutations in the same disease gene, for example, in the
inherited VHL gene, can have varying effects on cancer risk and prognosis [47]. The genetic
practitioner will assess the significance of the result for each family separately. It is useful to wait
until the age of 18 to allow an offspring to reach an age of consent in those inherited syndromes
in which the age of onset is in adulthood. However, the early age of onset in condition like VHL
could have devastating complications without early detection andmanagement, and therefore in
this syndrome predictive testing is recommended to at-risk children in family.
5. Genotype-phenotype correlation in kidney cancer
VHL is divided to subgroups for academic purposes according to the phenotype based on the
likelihood of pheochromocytoma or renal cell carcinoma. In the following some examples are
described. For example, a reduced risk for renal cell carcinoma in individuals has been
observed with a deletion of VHL [13]. A MET variant due to a mutation is associated with
early-onset HPRC disease [16]. The WT1 gene mutation may cause hereditary Wilms’ tumor
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without syndrome or with syndrome, like Denys-Drash, Frasier, or nephrotic syndrome type 4.
WT1 protein plays an important role in renal and gonadal development, due to which genital
abnormalities can be seen in Denys-Drash and Frasier syndrome. In Frasier syndrome patients
have progressive nephrotic syndrome, but incidence of Wilms’ tumor is rare. Mutations that are
responsible for Frasier syndrome are located in intron 9 inWT1 (an alternative splicing site). In
Denys-Drash syndrome, patients’ typical symptoms are progressive nephrotic syndrome that
early progresses to renal failure less than the age of 4 years. A majority of the Denys-Drash
patients have mutations located in exons 8 and 9. The risk of Wilms’ tumor is very high (90%).
6. The diagnostic impact of gene testing evolution
Multigene next generation sequencing (NGS) panel technology allows genes of interest to be
studied quickly and cost-effectively. By focused massive parallel sequencing, it is possible to
examine those exons of the genome’s genes that are of interest in diagnosing the cause of
inherited kidney cancer. The method can also investigate boundaries between exons and
introns. A gene panel for hereditary kidney cancer covers approximately 25 genes and can be
ordered from different companies. Clinical picture may sometimes indicate a mutation in
particular gene or genes, which can be separately examined. However, often hereditary muta-
tion may be in many different genes according to patient and family history, and then
multigene panel-based NGS will be more economical than Sanger or NGS sequencing of
several different genes. Sequencing results are obtained in about 4 weeks. The gene content of
the panels is regularly updated by laboratories as information on genes associated with kidney
cancer is published continuously. A limitation of parallel sequencing is that they cannot
recognize large intrinsic deletions or duplicates, and for this another method is required that
investigates exome CNVs. A majority of hereditary mutations are located in the exome region.
The whole genome NGS is not yet a routine method, but it is used in scientific studies. By the
NGS method, the diagnostic utility of hereditary cancers has been hugely improved.
Information on the clinical significance associated with mutations is reviewed in registers (e.g.,
InSiGHT and ClinVar) [48]. With the development of research techniques, more variants of
uncertain significance (VUS) are now observed. Currently, these are also variants of which it is
unknown whether they are benign or pathogenic and explain the patient’s predisposition to
cancer. In some situations, the variant may be classified as likely pathogenic. Prediction pro-
grams can be used to evaluate a variant’s ability to cause disease (in silico analysis) [49, 50]. For
example, the ExAC database can be used to check the prevalence of the variant in the popula-
tion. As techniques evolve, it is increasingly possible to study the functional change in RNA
structure caused by VUS alteration, which would be relevant to the quality of the resulting
protein. In order to clarify the nature of the uncertain variants, the geneticist may arrange the
so-called segregation analysis in family [49]. Finding the same hereditary variant from several
relatives with cancer would strengthen the conclusion that the variant explains the cases in the
family. Information is being collected internationally as laboratories collect VUS they observe
into databases and doctors publish case reports. However, in already well-known genes such
as BRCA and Lynch syndrome genes, VUS alterations are relatively rarely detected.
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During counseling, the geneticist will inform what is known about the significance of the identi-
fied variant. If the significance of the variant remains open, the geneticist and laboratory experts
may reclassify the change after few years. The increased use of multigene NGS panels in patient
work expands the knowledge on the different pathogenic variants in the human DNA. The
number of VUS changes will therefore decrease in the next few years [50]. It is important that
counseling provides reliable information on the examination results and therefore VUSmodifica-
tions are not used as a basis for prophylactic surgery or to determine the risk of relatives’ cancer.
7. Treatment in hereditary kidney cancer
For several RCC syndromes, studies have found that conservative management appears to
preserve renal function without increased mortality. In certain syndromes, such as HLRCC,
early and aggressive treatment may be preferable [17, 20]. Each subtype of RCC may need to
be treated differently by systemic therapy, but no phase III clinical trial data exist from
distinct treatments [51, 52]. The prognosis was inferior for papillary metastatic RCC (mRCC)
compared to clear cell mRCC when patients were treated with the same evidence-based
treatment in a study by Staehler [52]. The understanding of the metabolic and epigenetic
abnormalities underlying the symptoms of hereditary kidney cancer-associated genes may
lead to the development of novel diagnostic biomarkers and novel treatment modalities for
kidney cancer [53].
8. Surveillance in hereditary kidney cancer families
Recommendations for follow-up care should correspond to the level of risk associated with the
genetic variant tested [43]. The aim of the monitoring is to improve the early detection of
cancer in families with hereditary renal cancer. Monitoring recommendations includes regular
kidney imaging: the healthy carrier of a gene mutation predisposing to kidney cancer will
usually undergo abdominal MRI scans on a regular basis (Table 7). The frequency of follow-up
depends on the biological nature of the family syndrome. Several monitoring planes have been
proposed for hereditary kidney cancer syndromes, for example, by Freifeld [54] and Carlo [10].
Also, PDQ Cancer Information Summaries [55] has a suggestion for surveillance in certain
syndromes predisposing to hereditary renal cancer.
Tracking intervals may be less frequent, for example, for HPRC, and more frequent for others,
such as HLRCC in the case of an early onset of 10 years [56] and several reported cases among
children. However, the estimated risk of developing RCC before age 20 is estimated to be only
around 1–2%, whereas the lifetime risk of RCC among FH mutation carriers is approximately
15% [25]. In 2014, consensus guidelines from an international HLRCC symposium
recommended annual renal MRI starting at age 8 to 10 years, as also recommended by the
HLRCC Family Alliance and the French National Cancer Institute [25]. The starting age is still
variable. In HPRC patients, if the tumor smaller than 3 cm is found, imaging should be
repeated within the first year to assess the growth rate [55]. Generally, patients with renal
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tumors associated with HPRC are candidates for radiologic surveillance until one or more
tumors reach 3 cm. Ultrasound is not sufficient in surveillance of hereditary kidney cancer
syndromes [10, 25, 54, 55]. In the near future, more evidence on effective monitoring in
different kidney cancer syndromes will be gathered. If the gene mutation has not been identi-
fied but the family has a significantly increased risk of kidney cancer, a regular renal imaging
examination in the first-degree relative of the patient with renal cancer may be considered on a
case-by-case basis. Other surveillance procedures depend on the risks of the specific symptoms
in observed gene mutation. In multisystem syndromes, monitoring practices depend on the
probability of the kidney cancer, and ultrasound may be used in monitoring.
In Lynch syndrome, which is a high risk for upper tract ureotelic carcinoma, the risk of
colorectal cancer can be reduced by removing intestinal adenomas at regular checkups, which
results in the same mortality to colorectal cancer in the carriers of Lynch gene mutation as in
the general population.
9. Future perspectives
The contents of routine gene panels are based on the knowledge on kidney cancer susceptibil-
ity genes. If a patient’s DNA sequencing has failed to identify the hereditary mutation, RNA
sequencing may identify the specific diagnosis [57]. If there are three patients in the family, trio
exome analysis may be a pivotal method. Potentially, tumor tissue-only test would be a useful
method to find out novel kidney cancer susceptibility genes and mutations in kidney cancer
von Hippel-Lindau (VHL) Hereditary
papillary RCC
(HPRC)
Hereditary
leiomyomatosis and
RCC (HLRCC)
Birt-Hogg-Dubé
(BHD)
RCC subtype Clear cell carcinoma Papillary type 1 Papillary type 2,
collecting duct
Most often
chromophobe 
oncocytoma
Risk for RCC 40% Nearly 100% 20–30% 30%
Gene VHL MET FH FLCN(BHD)
Typical age of
onset for RCC
40 years 50–70 years Less than 40 years 50 years
Abdominal
magnetic
imaging
Annually starting at the age
of 10
Annually starting
at the age of 30
Annually starting at the
age of 5–20 years
Annually starting at
the age of 20 years
Other
surveillance
Biannual brain and spine
MRI starting at the age of 11
Ophthalmological and
audiological exam
Plasma-free metanephrines/
urinary metanephrines
None Dermatological and
gynecological exam
Dermatological exam
and CT of the chest
Table 7. Follow-up care recommendations in hereditary cancer syndromes inwhich the kidney cancer risk is high [10, 25, 54].
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patients, as the knowledge on hereditary kidney cancer genes is still limited. This investigation
is not available currently.
Tumor tissue-only gene tests by next generation sequencing with targeted genes may be soon
routinely used for cancer patients’ pharmacogenetic genotyping and analyzing their tumor
tissue’s somatic mutations to tailor their medical treatment [58]. The same method could be
also a first step analysis for identifying the hereditary cancer mutation in a gene that is known
in literature as a susceptibility gene. An additional test of patient’s peripheral lymphocyte
should then be used to confirm the susceptive mutation as hereditary mutation.
The growing knowledge on the biology of hereditary kidney cancer produces information
about driver genes in kidney cancer tumorigenesis and may develop diagnostics and thera-
peutic methods for kidney cancer in general [59]. Knowledge on evidence-based medicine in
metastatic hereditary kidney cancer [60] is under active study. Analysis of induced pluripotent
stem cells (iPSC) from HPRC pointed that drug screening and precision medicine are possible
for hereditary kidney cancer [61]. Preventive medicine may be achieved for healthy persons
with familial mutation predisposing to kidney cancer [61].
Prospective studies about the method of follow-up in healthy persons with family kidney
cancer susceptibility mutation are warranted. The optimal onset to start follow-up in FH-
related hereditary kidney cancer families should be clarified as currently there is no consensus.
It is known that the prognosis in early-stage kidney cancer disease is better than in later stages
[62]. Studies about long-term effect of surveillance in healthy carriers in hereditary kidney
cancer families are needed. Additionally, further research is needed to understand the actual
impact of genetic testing on young family members [63].
10. Conclusion
Knowledge on the clinical significance of mutations helps to improve prognosis in families
with hereditary cancer. Understanding of hereditary kidney cancer syndromes on their molec-
ular basis improves the utility of specific diagnosis [64]. In the future, increased knowledge of
cancer genetics is likely to enable the development of targeted drug therapies. Today, heredi-
tary mutations are detected by DNA testing of white blood cell lymphocytes. Tumor tissue-
only tests to identify the hereditary kidney cancer are not yet available.
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